The FDA expanded indications for imatinib mesylate tablets (Gleevec, Novartis) to include patients who have had CD117-positive gastrointestinal stromal tumors surgically removed.
Sign in with your MPR account
Keep me signed in Forgot your password?
REGISTER FOR FREE WITH A MPR ACCOUNT
Enter your MPR registration email address to receive a new password.